Has Drew Barrymore confirmed she uses HRT?

Barrymore has publicly discussed perimenopause and confirmed she has had conversations with her doctors about HRT. She has not disclosed a specific hormone therapy protocol or confirmed ongoing use of a particular medication.

What type of HRT is most commonly prescribed for perimenopause?

The most common approach is a combination of estradiol (for symptom relief) and micronized progesterone (for endometrial protection in women with an intact uterus). Delivery methods include oral tablets, transdermal patches, gels, and vaginal rings. The Menopause Society recommends starting at the lowest effective dose.

Does HRT cause weight loss?

Clinical evidence does not support HRT as a weight-loss intervention. Some data suggests it may reduce the shift toward central fat distribution that occurs during menopause, but significant overall weight loss is not an expected outcome of hormone therapy.

How long can you stay on HRT?

There is no fixed maximum duration. The FDA recommends the lowest dose for the shortest duration needed. In practice, many women use HRT for several years, with annual reassessment of symptoms and risks. Some continue low-dose therapy into their 60s under medical supervision.

Is HRT safe for everyone?

No. Women with a history of breast cancer, active liver disease, unexplained vaginal bleeding, or a history of blood clots may not be candidates for systemic HRT. The risk-benefit assessment should be individualized with a clinician who understands the patient's full medical history.

The Medical Takeaways from Drew Barrymore's Women's HRT Story

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for The Medical Takeaways from Drew Barrymore's Women's HRT Story Image: HealthRX.com clinical image

What Drew Barrymore Has Said Publicly

Barrymore has been candid about entering perimenopause in her late 40s. On The Drew Barrymore Show, she discussed experiencing weight fluctuations, mood shifts, and the frustration of not understanding what was happening to her body. In multiple on-air conversations with guests and medical professionals, she acknowledged that hormone replacement therapy was part of the conversation she was having with her own doctors.

She has confirmed publicly that perimenopause affected her physically and emotionally. She has discussed HRT as something she was exploring and open to. What she has not done is provide a detailed account of a specific HRT regimen, dosage, or duration. That distinction matters. The public record supports that Barrymore has confirmed awareness of and openness to HRT, not that she has disclosed a specific protocol.

In a 2023 interview segment, Barrymore stated she wanted to be honest about the changes she was experiencing because "nobody told me this was coming." That sentiment echoes a complaint the North American Menopause Society has documented repeatedly: most women receive little or no anticipatory guidance about perimenopause.

Why This Public Conversation Matters Clinically

A 2024 survey published by the Menopause Society found that fewer than 40% of women experiencing perimenopausal symptoms had discussed treatment options with a clinician. When a mainstream figure like Barrymore discusses these symptoms on national television, it reduces the stigma barrier that keeps many patients silent.

The HealthRX.com Medical Team sees Barrymore's public discussion as clinically valuable for one reason: it gives patients permission to ask questions. Too many women assume that hot flashes, sleep disruption, and mood instability are things they simply have to endure. They are not. HRT is one of several evidence-based treatment options, and understanding what it actually does (and does not do) is the first step toward an informed conversation with a prescriber.

HRT 101: Mechanism and Core Pharmacology

Hormone replacement therapy for perimenopausal and postmenopausal women typically involves estrogen, progesterone, or a combination of both. The 2022 Hormone Therapy Position Statement from The Menopause Society reaffirms that systemic HRT remains the most effective treatment for vasomotor symptoms (hot flashes and night sweats) and the genitourinary syndrome of menopause.

Estrogen is the primary driver of symptom relief. It acts on estrogen receptors throughout the body, including the hypothalamus (which regulates thermoregulation), vaginal and urethral tissue, bone, and the cardiovascular system. Formulations include oral estradiol, transdermal patches, gels, and sprays.

Progesterone (or a synthetic progestin) is added for any woman who still has a uterus. Without it, unopposed estrogen stimulates the endometrial lining and raises the risk of endometrial hyperplasia and cancer. Micronized progesterone (brand name Prometrium) is the most commonly prescribed bioidentical option.

Dose ranges vary by formulation. Oral estradiol typically starts at 0.5 mg to 1 mg daily. Transdermal estradiol patches deliver 0.025 mg to 0.1 mg per day. Micronized progesterone is usually dosed at 100 mg to 200 mg nightly for 12 to 14 days per cycle, or 100 mg continuously. The FDA prescribing guidance recommends the lowest effective dose for the shortest duration consistent with treatment goals.

Expected Benefits: What Patients Should Realistically Expect

HRT does not produce overnight changes. Most women begin noticing a reduction in hot flash frequency within two to four weeks. Full vasomotor symptom control typically takes four to twelve weeks. Sleep quality often improves as night sweats decrease, and many women report secondary improvements in mood, concentration, and energy as a result.

The WHI follow-up data showed that women who initiated HRT within 10 years of menopause onset (or before age 60) had a favorable risk-benefit profile, including reduced fracture risk and potential cardiovascular benefit.

What HRT does not reliably do: it is not a weight-loss intervention. Barrymore's public discussion of weight changes during perimenopause is relatable, but the clinical evidence on HRT and body composition is mixed. A 2021 meta-analysis in Maturitas found that HRT may attenuate the increase in central adiposity associated with menopause, but it does not produce significant overall weight loss. Patients who start HRT expecting the scale to move dramatically will likely be disappointed.

Side Effects: The Realities Nobody Glamorizes on Television

Every HRT regimen carries a side-effect profile. The HealthRX.com Medical Team encourages patients to review these before starting therapy, not after.

Common early side effects (first one to three months):

Breast tenderness or swelling
Irregular bleeding or spotting (especially with cyclic progesterone)
Bloating and fluid retention
Headaches
Nausea (primarily with oral formulations)

Rare but serious risks:

Venous thromboembolism (VTE). Oral estrogen raises VTE risk by roughly two to fourfold compared to non-use, per a 2019 BMJ analysis. Transdermal estrogen does not carry this same elevated risk, making it the preferred route for women with thrombotic risk factors.
Breast cancer. The WHI data showed a small increased risk of breast cancer with combined estrogen-progestin therapy (approximately 8 additional cases per 10,000 women-years), while estrogen-only therapy did not increase breast cancer risk over a 20-year follow-up.
Stroke risk modestly increases with oral estrogen, particularly in women who start HRT after age 60.

The HealthRX.com Medical Team notes that the side-effect conversation should always be personalized. A 48-year-old nonsmoker with no family history of breast cancer and debilitating vasomotor symptoms has a very different risk calculus than a 62-year-old with a first-degree relative who had breast cancer.

Discontinuation: The Part of HRT Nobody Talks About

One area Barrymore's public comments touch on indirectly is the emotional weight of making medical decisions about hormones. What the public conversation rarely includes is what happens when women stop HRT.

Abrupt discontinuation leads to symptom rebound in approximately 50% of women, regardless of how long they have been on therapy. Hot flashes, night sweats, and sleep disruption can return at their original severity or worse. The HealthRX.com Medical Team recommends a gradual taper over two to six months, reducing the estrogen dose in stepwise increments.

There is no universal "right time" to stop. The Menopause Society's current position is that ongoing therapy should be re-evaluated annually based on the patient's symptom burden, risk factors, and preferences. Some women use low-dose HRT well into their 60s with appropriate monitoring. Others stop within two to three years once their vasomotor symptoms resolve naturally.

The HealthRX.com Medical Team Take

Barrymore's public openness about perimenopause did something that clinical guidelines cannot: it made millions of women feel less alone. From a medical perspective, her story illustrates three things the HealthRX.com Medical Team believes every patient considering HRT should understand.

First, perimenopause is not "just aging." It is a defined endocrine transition with identifiable symptoms and evidence-based treatments. The fact that Barrymore described feeling blindsided by her symptoms reflects a systemic failure in anticipatory care.

Second, considering HRT is not the same as committing to it forever. The decision to start, the decision about which formulation, and the decision about when to stop are three separate clinical conversations. Each one deserves its own risk-benefit analysis.

Third, celebrity stories are starting points, not treatment plans. Barrymore's willingness to discuss HRT publicly is valuable. But the clinical details (which formulation, what dose, how long, what monitoring) require an individualized assessment that no talk-show segment can provide.

Women watching Barrymore's segments should take away one actionable message: if you are experiencing perimenopausal symptoms, bring them up with your doctor. The conversation itself is the first step, and it is one that too many women are still skipping.

At a glance

Drew Barrymore has publicly confirmed experiencing perimenopause and has discussed HRT as part of her medical conversations.
She has not disclosed a specific HRT regimen, dosage, or duration.
HRT remains the most effective treatment for vasomotor symptoms per the Menopause Society's 2022 position statement.
Transdermal estrogen carries lower VTE risk than oral formulations.
HRT is not a reliable weight-loss tool, despite associations between perimenopause and body composition changes.
Discontinuation should be gradual; abrupt cessation causes symptom rebound in roughly half of women.
The decision to start, adjust, or stop HRT should be individualized and reviewed annually.

Frequently asked questions

›